Everest Licensing Partner Pfizer Presents Results of Etrasimod in P-III (ELEVATE UC 12 & 52) Studies for the Treatment of Ulcerative Colitis at DDW 2022
Shots:
- The P-III (ELEVATE UC 12 & 52) studies evaluating etrasimod (2mg, qd) vs PBO in patients with active UC. The therapy was developed by Arena & recently acquired by Pfizer
- The studies achieved all 1EPs & 2EPs i.e., clinical remission in (ELEVATE UC 52) study was (27.0% vs 7.4%) @12wk. & (32.1% vs 6.7%) @52wk., In the 12wk. (EVATE UC 12) study, (24.8% vs 15.2%). The safety profile was consistent with prior studies
- Additionally, endoscopic improvement, symptomatic remission & mucosal healing @12 & 52wk. in both studies while corticosteroid-free remission & sustained clinical remission @52wk., AEs & SAEs were similar b/w groups. The company will use these results for future regulatory filings which are expected to be initiated in 2022
Ref: PRNewswire | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
